Search PubMed⌕ Search

Biomedical subjects

G Tougas

Publications and source records attributed to G Tougas.

76 records · Page 5Linked to original sources
PubMedDate not supplied

VIP receptors on canine submucosal synaptosomes.

The present study characterized [125I]VIP binding to synaptosomes from the submucosa of canine small intestine. Studies of saturation, competition binding, and kinetic studies revealed high- and low-affinity binding sites. Studies with GTP-gamma-S and cholera toxin suggested that the receptor was coupled to a G-protein, possibly Gs. Competition with VIP analogs suggested that the N-terminal end of the molecule played the major role in determining affinity and that this receptor was for VIP, not PACAP. Cross-linking VIP to the receptor revealed a single peptide (M(r) congruent to 60,000). We suggest that VIP may act to modulate mediator release from enteric nerve endings.

Animals↗
PubMedDate not supplied

The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts.

Gastroesophageal reflux disease (GERD) is a disease with serious consequences that may result in significant impairment in quality of life and disease morbidity. Across all grades of severity of symptoms and severity of underlying esophageal disease, proton pump inhibitors (PPIs) provide therapeutic gains over prokinetics (PKs) or H2 receptor antagonists (H2RAs). The potential cost effectiveness of using medications with higher acquisition costs that may lower health care costs overall is often disregarded when conducting cost comparisons with medications having lower 'up-front' costs. Limiting therapy to less effective agents condemns many patients to protracted suffering, repeated physician visits and needless reinvestigation of symptoms that could have been resolved by appropriate initial therapy. Based on current data, use of any classification of symptom severity as a basis for selecting one class of therapeutic agents over another for first line therapy (i.e. PKs, H2RAs for 'mild' GERD, versus a PPI for 'severe' disease) is unwarranted.

Cost of Illness↗
PubMedDate not supplied

Evidence for anti-inflammatory effect of normal circulating plasma cortisol.

Joint pain and tenderness increased significantly during metyrapone tests in 21 patients with rheumatoid arthritis who had never received corticosteroid therapy and who had no evidence of endocrine disease. This observation implies that the normal circulating plasma corticol exerts an anti-inflammatory effect.

Anti-Inflammatory Agents↗